MedTrace Logo

Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

NCT01020968 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-05-27

No results posted yet for this study

Summary

This study is designed to assess the safety profile and the efficacy of cardiac repair cells (CRCs) administered via catheter in treating patients with dilated cardiomyopathy (DCM).

Conditions

  • Dilated Cardiomyopathy

Interventions

BIOLOGICAL

Ixmyelocel-T

CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.

OTHER

Vehicle Control

will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.

Sponsors & Collaborators

  • Vericel Corporation

    lead INDUSTRY

Principal Investigators

  • Timothy Henry, MD · Minneapolis Heart Institute Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
86 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-01-11
Completion
2013-12-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01020968 on ClinicalTrials.gov